OncRef

Clinical Trial: NCT06458413

Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Min Yan, MD
Information Provided By:Henan Cancer Hospital
Last Update Posted:2026-10-16

Study Overview

Brief Summary

This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients.

This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.

Official Title

:Single-arm, Phase II Clinical Trial of Utidelone Capsule Plus Capecitabine (CAP) in Patients With Metastatic Breast Cancer

Conditions

Breast Cancer Recurrent

Intervention / Treatment

  • Drug: Utidelone Capsule Plus Capecitabine

Other Study ID Numbers

  • HNCH-MBC16

Start Date (Actual)

2024-06-06

Primary Completion Date (Actual)

2026-07-09

Study Completion Date (Estimated)

2026-12-30

Enrollment (Estimated)

40

Study Type

Interventional

Phase

Phase 2